Dr. Dinesh Khanna from the University of Michigan Health System recently presented at the European League Against Rheumatism (EULAR) 2015 Annual European Congress of Rheumatology in Rome new positive safety data regarding ESBRIET for the treatment of interstitial lung disease (ILD). ILD is a group of disorders that cause progressive…
A new study recently published in the journal PLoS One reported data on a specific imaging tool to assess disease progression in patients with idiopathic pulmonary fibrosis (IPF). The study was conducted by an international research team and is entitled “Visual vs Fully Automatic…
In a new study entitled “Ultrasound signs of pulmonary fibrosis in systemic sclerosis as timely indicators for chest computed tomography,” authors show thoracic ultrasound allows clinical staff to identify early signs of pulmonary fibrosis in systemic sclerosis patients who fail to exhibit symptoms. The study was published…
A study recently published in the journal PloS One revealed that patients with acute exacerbations of idiopathic pulmonary fibrosis (IPF) may benefit from treatments similar to the ones employed in autoimmune diseases. The study is entitled “Autoantibody-Targeted Tratments for Acute Exacerbations of Idiopathic Pulmonary…
Researchers at the University of Georgia and the Georgia Regents University discovered that the drug triciribine can halt the progression of fatal respiratory diseases like pulmonary fibrosis and pulmonary hypertension. The study was recently published in the British Journal of Pharmacology and is entitled “…
The Medical Advisory Board of the Pulmonary Fibrosis Foundation (PFF) recently released an announcement regarding therapies based on stem cells for the treatment of idiopathic pulmonary fibrosis (IPF). IPF is a progressive, fatal lung disease in which the alveoli and the lung tissue are damaged, becoming thick and scarred…
Researchers at the Medical School of Nanjing University in China recently published in the journal Respirology findings that reveal how shorter telomeres in chromosomes are associated with a poor survival in patients with idiopathic pulmonary fibrosis (IPF). The study is entitled “Association between telomere…
Dr. Claudia A. Staab-Weijnitz and Dr. Oliver Eickelberg at the Comprehensive Pneumology Center in the University of Munich are studying a new drug target for idiopathic pulmonary fibrosis (IPF) that addresses a protein potentially involved in the pathway of IPF pathogenesis. By attenuating the protein in a model of IPF,…
Clinical stage biotech company Promedior Inc. will present data from its ongoing phase 2 clinical trial of their lead investigational therapy candidate for myelofibrosis at the 20th Congress of the European Hematology Association (EHA) taking place between June 1st and 14th in Vienna, Austria. The presentation on PRM-151, which is also being…
Pacific Therapeutics Ltd., a clinical stage pharmaceutical company that repurposes and reformulates already approved drugs for larger markets such as cystic fibrosis, recently announced that the United States Patent Office (USPO) has issued United States Patent No. 9029385 for its patent application, “Compositions and Methods for Treating Fibroproliferative Disorders.”…
Get regular updates to your inbox.
